BioNTech SE ADR closed $10.99 short of its 52-week high ($115.99), which the company reached on September 14th.

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

Analyst John Newman of Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), retaining the price target of ...

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

J.P. Morgan analyst Jessica Fye maintained a Sell rating on BioNTech SE (BNTX – Research Report) today and set a price target of $91.00.

The newest, updated Covid-19 vaccines are now FDA-approved and available, including the mRNA ones from Pfizer-BioNTech and ...

MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology ...

Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or ...

Tempus AI, Inc. (NASDAQ: TEM, "Tempus"), a technology company leading the adoption of AI to advance precision medicine and ...

The UK has become the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine, paving the way for mass vaccination. Britain's medicines regulator, the MHRA, says the jab, which ...

BioNTech SE ADR closed $19.25 below its 52-week high ($119.78), which the company achieved on September 11th.